Synopsis
Recognise when an environmental non-tuberculous mycobacterium represents progressive pulmonary disease rather than transient isolation, and frame diagnosis, observation and species-led multidrug treatment safely with an experienced NTM service. Confirm treatment decisions against current BTS guidance, microbiology advice and local policy.
- A positive culture is not synonymous with disease: combine compatible symptoms, characteristic imaging and reproducible microbiology, while excluding tuberculosis and convincing alternatives.
- Bronchiectasis, COPD, previous tuberculosis, cystic fibrosis, thoracic skeletal abnormality, low body mass and immune compromise increase susceptibility, but NTM can also occur without an obvious host defect.
- Send at least two sputum samples collected on separate days for mycobacterial culture; ask for species or subspecies identification and appropriate susceptibility testing.
Key red flags
Upper-lobe cavities, pleural thickening, weight loss, night sweats and haemoptysis can closely mimic pulmonary tuberculosis or malignancy. COPD, smoking-related lung damage and previous TB are common backgrounds.
Investigation priorities
Obtain at least two expectorated samples on separate days, ideally before NTM-active antibiotics, and request acid-fast microscopy, culture and species-level identification.
Management branches
An NTM is reported from a respiratory specimen.
- Review symptoms, specimen quality, species identity, smear burden, exposures, immune state and previous imaging; urgently retain TB precautions if M. tuberculosis complex remains plausible.
- Arrange high-resolution CT and further sputum cultures on separate days; use bronchoscopy only when it will materially resolve uncertainty and the patient can tolerate it.
Diagnostic criteria are met or nearly met, but disease is mild and stable and treatment harm may exceed near-term benefit.